RESOURCE USE AND HEALTH-CARE COSTS OF CHRONIC LYMPHOCYTIC LEUKEMIA IN SLOVAKIA
Author(s)
Ondrusova M1, Suchansky M1, Chudej J2, Psenkova M3
1Pharm-In Ltd, Bratislava, Slovak Republic, 2University hospital Martin, Martin, Slovak Republic, 3Pharm-In Ltd, Bratislava, Slovakia
OBJECTIVES: The objective of this study was to measure the resource utilisation and the direct costs associated with health-care management of chronic lymphocytic leukemia (CLL) in Slovakia and to provide a basis for cost-effectiveness evaluations. METHODS: The extended cross-sectional survey was performed according to internationally accepted recommendations. The survey, conducted through the Key Opinion Leaders, was performed to obtain the information on the management of patients with CLL and to estimate the direct costs of the disease management. The working group included experts from all the onco-hematology centers in Slovakia. The primary population studied was the cohort of adult patients with CLL, with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine based therapy The cost-data were analysed according to the first-line treatment and were assessed for the year 2017. All types of health care used were evaluated. Costs of adverse events (AEs) were set for treatment of one single event. RESULTS: The most frequent treatment regimens used in the 1st treatment line of CLL patients not suitable for fludarabine regimen was rituximab+bendamustine (43.30%), followed by ofatumumab+bendamustine (28.26%), obinutuzumab+chlorambucil (23.93%) and rituximab+chlorambucil (4.51%). The most frequent 2nd line treatment after rituximab+bendamustine in early versus late progression was methylprednisone versus rituximab+bendamustine (30% versus 86.32%). Weekly cost of CLL management in stable disease were highest in rituximab+bendamustine treatment (€ 36.27/patient), followed by ofatumumab+bendamustine (35.80 €/patient), obinutuzumab+chlorambucile (€ 35.62/patient), rituximab+chlorambucil (€ 35.23/patient). Cost for treating AEs were evaluated for grade 3/4. The most costly AEs were febrile neutropenia (€ 1 703.22), thrombocytopenia (€ 1 265.71) and anaemia (€ 817.55). CONCLUSIONS: In order to prove the cost-effectiveness, the local resource use data need to be collected, which are key drivers for health-economic modelling and can guide resource allocation decisions in CLL in Slovakia. This survey provides information to support these decisions.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN100
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology